Tomasz (Tom) Beer

Professor

  • 15948 Citations
  • 56 h-Index
1976 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

2020

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

Graff, J. N., Beer, T. M., Alumkal, J. J., Slottke, R. E., Redmond, W. L., Thomas, G. V., Thompson, R. F., Wood, M. A., Koguchi, Y., Chen, Y., Latour, E., Bergan, R. C., Drake, C. G. & Moran, A. E., Jul 2 2020, In : Journal for immunotherapy of cancer. 8, 2, e00642.

Research output: Contribution to journalArticle

Open Access

Association between New Unconfirmed Bone Lesions and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials

Armstrong, A. J., Al-Adhami, M., Lin, P., Parli, T., Sugg, J., Steinberg, J., Tombal, B., Sternberg, C. N., De Bono, J., Scher, H. I. & Beer, T. M., Feb 2020, In : JAMA Oncology. 6, 2, p. 217-225 9 p.

Research output: Contribution to journalArticle

Open Access
2 Scopus citations

Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer

Kwon, D. H., Zhang, L., Quigley, D. A., Foye, A., Chen, W. S., Wong, C. K., Feng, F. Y., Bailey, A., Huang, J., Stuart, J. M., Friedl, V., Weinstein, A. S., Beer, T. M., Alumkal, J., Rettig, M., Gleave, M., Lara, P. N., Thomas, G. V., Li, P., Lui, A. & 2 others, Small, E. J. & Aggarwal, R. R., 2020, (Accepted/In press) In : Urologic Oncology: Seminars and Original Investigations.

Research output: Contribution to journalArticle

Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial

Armstrong, A. J., Lin, P., Tombal, B., Saad, F., Higano, C. S., Joshua, A. M., Parli, T., Rosbrook, B., van Os, S. & Beer, T. M., Sep 2020, In : European Urology. 78, 3, p. 347-357 11 p.

Research output: Contribution to journalArticle

1 Scopus citations

Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer

Chen, W. S., Feng, E. L., Aggarwal, R., Foye, A., Beer, T. M., Alumkal, J. J., Gleave, M., Chi, K. N., Reiter, R. E., Rettig, M. B., Evans, C. P., Small, E. J., Sharifi, N. & Zhao, S. G., Jun 1 2020, In : Prostate Cancer and Prostatic Diseases. 23, 2, p. 316-323 8 p.

Research output: Contribution to journalArticle

1 Scopus citations
2019

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

Kapoor, R., Deek, M. P., McIntyre, R., Raman, N., Kummerlowe, M., Chen, I., Gaver, M., Wang, H., Denmeade, S., Lotan, T., Paller, C., Markowski, M., Carducci, M., Eisenberger, M., Beer, T. M., Song, D. Y., Deweese, T. L., Hearn, J. W., Greco, S., Deville, C. & 7 others, Desai, N. B., Heath, E. I., Liauw, S., Spratt, D. E., Hung, A. Y., Antonarakis, E. S. & Tran, P. T., Jun 13 2019, In : BMC cancer. 19, 1, 572.

Research output: Contribution to journalArticle

Open Access

Combining options in metastatic prostate cancer

Kopp, R. & Beer, T. T., Jan 1 2019, In : Nature Reviews Urology.

Research output: Contribution to journalComment/debate

Correction: Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer (Clinical Cancer Research (2019) 25 (52-63) DOI: 10.1158/1078-0432.CCR-18-1589)

Ferrari, A. C., Alumkal, J. J., Stein, M. N., Taplin, M. E., Babb, J., Barnett, E. S., Gomez-Pinillos, A., Liu, X., Moore, D., DiPaola, R. & Beer, T. M., Apr 15 2019, In : Clinical Cancer Research. 25, 8, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer

Ferrari, A. C., Alumkal, J., Stein, M. N., Taplin, M. E., Babb, J., Barnett, E. S., Gomez-Pinillos, A., Liu, X., Moore, D., DiPaola, R. & Beer, T. T., Jan 1 2019, In : Clinical Cancer Research. 25, 1, p. 52-63 12 p.

Research output: Contribution to journalArticle

7 Scopus citations

Erratum to: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy (Nature Communications, (2018), 9, 1, (4972), 10.1038/s41467-018-07411-7)

Geng, H., Xue, C., Mendonca, J., Sun, X. X., Liu, Q., Reardon, P. N., Chen, Y., Qian, K., Hua, V., Chen, A., Pan, F., Yuan, J., Dang, S., Beer, T. M., Dai, M. S., Kachhap, S. K. & Qian, D. Z., Dec 1 2019, In : Nature communications. 10, 1, 164.

Research output: Contribution to journalComment/debate

Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer(Figure presented.)

Chen, W. S., Aggarwal, R., Zhang, L., Zhao, S. G., Thomas, G. V., Beer, T. M., Quigley, D. A., Foye, A., Playdle, D., Huang, J., Lloyd, P., Lu, E., Sun, D., Guan, X., Rettig, M., Gleave, M., Evans, C. P., Youngren, J., True, L., Lara, P. & 8 others, Kothari, V., Xia, Z., Chi, K. N., Reiter, R. E., Maher, C. A., Feng, F. Y., Small, E. J. & Alumkal, J. J., Nov 2019, In : European Urology. 76, 5, p. 562-571 10 p.

Research output: Contribution to journalArticle

15 Scopus citations
4 Scopus citations

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

Nickols, N. G., Nazarian, R., Zhao, S. G., Tan, V., Uzunangelov, V., Xia, Z., Baertsch, R., Neeman, E., Gao, A. C., Thomas, G. V., Howard, L., De Hoedt, A. M., Stuart, J., Goldstein, T., Chi, K., Gleave, M. E., Graff, J. N., Beer, T. M., Drake, J. M., Evans, C. P. & 11 others, Aggarwal, R., Foye, A., Feng, F. Y., Small, E. J., Aronson, W. J., Freedland, S. J., Witte, O. N., Huang, J., Alumkal, J. J., Reiter, R. E. & Rettig, M. B., Dec 1 2019, In : Prostate Cancer and Prostatic Diseases. 22, 4, p. 531-538 8 p.

Research output: Contribution to journalArticle

Open Access
8 Scopus citations

Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial

Armstrong, A. J., Lin, P., Higano, C. S., Iversen, P., Sternberg, C. N., Tombal, B., Phung, D., Parli, T., Krivoshik, A. & Beer, T. M., Nov 1 2019, In : European urology oncology. 2, 6, p. 677-684 8 p.

Research output: Contribution to journalArticle

Open Access
3 Scopus citations

Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs

Layton, J. L., Lewis, B., Ryan, C., Beer, T. M. & Sartor, O., Mar 2019, In : Oncologist. 24, 3, p. 291-292 2 p.

Research output: Contribution to journalComment/debate

Whole-genome and transcriptional analysis of treatment-emergent small-cell neuroendocrine prostate cancer demonstrates intraclass heterogeneity

Aggarwal, R. R., Quigley, D. A., Huang, J., Zhang, L., Beer, T. M., Rettig, M. B., Reiter, R. E., Gleave, M. E., Thomas, G. V., Foye, A., Playdle, D., Lloyd, P., Chi, K. N., Evans, C. P., Lara, P. N., Feng, F. Y., Alumkal, J. J. & Small, E. J., Jun 1 2019, In : Molecular Cancer Research. 17, 6, p. 1235-1240 6 p.

Research output: Contribution to journalArticle

5 Scopus citations
2018

Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study

Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., Lloyd, P., Gleave, M., Evans, C. P., Youngren, J., Beer, T. M., Rettig, M., Wong, C. K., True, L., Foye, A., Playdle, D. & 11 others, Ryan, C. J., Lara, P., Chi, K. N., Uzunangelov, V., Sokolov, A., Newton, Y., Beltran, H., Demichelis, F., Rubin, M. A., Stuart, J. M. & Small, E. J., Aug 20 2018, In : Journal of Clinical Oncology. 36, 24, p. 2492-2503 12 p.

Research output: Contribution to journalArticle

107 Scopus citations

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

Armstrong, A. J., Lin, P., Higano, C. S., Sternberg, C. N., Sonpavde, G., Tombal, B., Templeton, A. J., Fizazi, K., Phung, D., Wong, E. K., Krivoshik, A. & Beer, T. M., 2018, In : Annals of Oncology. 29, 11, p. 2200-2207 8 p.

Research output: Contribution to journalArticle

11 Scopus citations

DNA repair gene alterations and PARP inhibitor response in patients with metastatic castration-resistant prostate cancer

Lu, E., Thomas, G. V., Chen, Y., Wyatt, A. W., Lloyd, P., Youngren, J., Quigley, D., Bergan, R., Bailey, S., Beer, T. M., Feng, F. Y., Small, E. J. & Alumkal, J. J., Aug 1 2018, In : JNCCN Journal of the National Comprehensive Cancer Network. 16, 8, p. 933-937 5 p.

Research output: Contribution to journalArticle

3 Scopus citations

Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039))

Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., Playdle, D., Barnard, T. J., Zhang, L., Zhang, J., Youngren, J. F., Cieslik, M. P., Parolia, A., Beer, T. M., Thomas, G., Chi, K. N. & 43 others, Gleave, M., Lack, N. A., Zoubeidi, A., Reiter, R. E., Rettig, M. B., Witte, O., Ryan, C. J., Fong, L., Kim, W., Friedlander, T., Chou, J., Li, H., Das, R., Li, H., Moussavi-Baygi, R., Goodarzi, H., Gilbert, L. A., Lara, P. N., Evans, C. P., Goldstein, T. C., Stuart, J. M., Tomlins, S. A., Spratt, D. E., Cheetham, R. K., Cheng, D. T., Farh, K., Gehring, J. S., Hakenberg, J., Liao, A., Febbo, P. G., Shon, J., Sickler, B., Batzoglou, S., Knudsen, K. E., He, H. H., Huang, J., Wyatt, A. W., Dehm, S. M., Ashworth, A., Chinnaiyan, A. M., Maher, C. A., Small, E. J. & Feng, F. Y., Oct 18 2018, In : Cell. 175, 3, p. 889 1 p.

Research output: Contribution to journalComment/debate

8 Scopus citations

Evolving intersection between inherited cancer genetics and therapeutic clinical trials in prostate cancer: A white paper from the germline genetics working group of the prostate cancer clinical trials consortium

Carlo, M. I., Giri, V. N., Paller, C. J., Abida, W., Alumkal, J., Beer, T. M., Beltran, H., George, D. J., Heath, E. I., Higano, C. S., McKay, R. R., Morgans, A. K., Patnaik, A., Ryan, C. J., Schaeffer, E. M., Stadler, W. M., Taplin, M. E., Kauff, N. D., Vinson, J., S.Antonarakis, E. & 1 others, Cheng, H. H., 2018, In : JCO Precision Oncology. 2

Research output: Contribution to journalArticle

8 Scopus citations

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., Playdle, D., Barnard, T. J., Zhang, L., Zhang, J., Youngren, J. F., Cieslik, M. P., Parolia, A., Beer, T. M., Thomas, G., Chi, K. N. & 43 others, Gleave, M., Lack, N. A., Zoubeidi, A., Reiter, R. E., Rettig, M. B., Witte, O., Ryan, C. J., Fong, L., Kim, W., Friedlander, T., Chou, J., Li, H., Das, R., Li, H., Moussavi-Baygi, R., Goodarzi, H., Gilbert, L. A., Lara, P. N., Evans, C. P., Goldstein, T. C., Stuart, J. M., Tomlins, S. A., Spratt, D. E., Cheetham, R. K., Cheng, D. T., Farh, K., Gehring, J. S., Hakenberg, J., Liao, A., Febbo, P. G., Shon, J., Sickler, B., Batzoglou, S., Knudsen, K. E., He, H. H., Huang, J., Wyatt, A. W., Dehm, S. M., Ashworth, A., Chinnaiyan, A. M., Maher, C. A., Small, E. J. & Feng, F. Y., Jul 26 2018, In : Cell. 174, 3, p. 758-769.e9

Research output: Contribution to journalArticle

101 Scopus citations
7 Scopus citations

Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

Geng, H., Xue, C., Mendonca, J., Sun, X. X., Liu, Q., Reardon, P. N., Chen, Y., Qian, K., Hua, V., Chen, A., Pan, F., Yuan, J., Dang, S., Beer, T. M., Dai, M. S., Kachhap, S. K. & Qian, D. Z., Dec 1 2018, In : Nature communications. 9, 1, 4972.

Research output: Contribution to journalArticle

9 Scopus citations

LSD1 activates a lethal prostate cancer gene network independently of its demethylase function

Sehrawat, A., Gao, L., Wang, Y., Bankhead, A., McWeeney, S. K., King, C. J., Schwartzman, J., Urrutia, J., Bisson, W. H., Coleman, D. J., Joshi, S. K., Kim, D. H., Sampson, D. A., Weinmann, S., Kallakury, B. V. S., Berry, D. L., Haque, R., Van Den Eeden, S. K., Sharma, S., Bearss, J. & 4 others, Beer, T. M., Thomas, G. V., Heiser, L. M. & Alumkal, J. J., May 1 2018, In : Proceedings of the National Academy of Sciences of the United States of America. 115, 18, p. E4179-E4188

Research output: Contribution to journalArticle

44 Scopus citations

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 [Figure presented]

Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., Daugaard, G., Davis, I. D., de Bono, J., Borges dos Reis, R., Drake, C. G., Eeles, R., Efstathiou, E., Evans, C. P., Fanti, S., Feng, F. & 41 others, Fizazi, K., Frydenberg, M., Gleave, M., Halabi, S., Heidenreich, A., Higano, C. S., James, N., Kantoff, P., Kellokumpu-Lehtinen, P. L., Khauli, R. B., Kramer, G., Logothetis, C., Maluf, F., Morgans, A. K., Morris, M. J., Mottet, N., Murthy, V., Oh, W., Ost, P., Padhani, A. R., Parker, C., Pritchard, C. C., Roach, M., Rubin, M. A., Ryan, C., Saad, F., Sartor, O., Scher, H., Sella, A., Shore, N., Smith, M., Soule, H., Sternberg, C. N., Suzuki, H., Sweeney, C., Sydes, M. R., Tannock, I., Tombal, B., Valdagni, R., Wiegel, T. & Omlin, A., Feb 2018, In : European Urology. 73, 2, p. 178-211 34 p.

Research output: Contribution to journalArticle

234 Scopus citations

Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: The PREVAIL randomized clinical trial

Rathkopf, D. E., Beer, T. M., Loriot, Y., Higano, C. S., Armstrong, A. J., Sternberg, C. N., De Bono, J. S., Tombal, B., Parli, T., Bhattacharya, S., Phung, D., Krivoshik, A., Scher, H. I. & Morris, M. J., May 2018, In : JAMA Oncology. 4, 5, p. 694-701 8 p.

Research output: Contribution to journalArticle

16 Scopus citations
2017

Analysis of circulating cell-free DnA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors

Quigley, D., Alumkal, J. J., Wyatt, A. W., Kothari, V., Foye, A., Lloyd, P., Aggarwal, R., Kim, W., Lu, E., Schwartzman, J., Beja, K., Annala, M., Das, R., Diolaiti, M., Pritchard, C., Thomas, G., Tomlins, S., Knudsen, K., Lord, C. J., Ryan, C. & 5 others, Youngren, J., Beer, T. M., Ashworth, A., Small, E. J. & Feng, F. Y., Sep 2017, In : Cancer discovery. 7, 9, p. 999-1005 7 p.

Research output: Contribution to journalArticle

87 Scopus citations

Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo

Taplin, M. E., Armstrong, A. J., Lin, P., Krivoshik, A., Phung, D., Parli, T., Tombal, B. & Beer, T. T., 2017, (Accepted/In press) In : Journal of Urology.

Research output: Contribution to journalArticle

6 Scopus citations

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer

Wyatt, A. W., Annala, M., Aggarwal, R., Beja, K., Feng, F., Youngren, J., Foye, A., Lloyd, P., Nykter, M., Beer, T. M., Alumkal, J. J., Thomas, G. V., Reiter, R. E., Rettig, M. B., Evans, C. P., Gao, A. C., Chi, K. N., Small, E. J. & Gleave, M. E., Dec 1 2017, In : Journal of the National Cancer Institute. 109, 12

Research output: Contribution to journalArticle

88 Scopus citations

CT–Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield

Holmes, M. G., Foss, E., Joseph, G., Foye, A., Beckett, B., Motamedi, D., Youngren, J., Thomas, G. V., Huang, J., Aggarwal, R., Alumkal, J. J., Beer, T. M., Small, E. J. & Link, T. M., Aug 2017, In : Journal of Vascular and Interventional Radiology. 28, 8, p. 1073-1081.e1

Research output: Contribution to journalArticle

15 Scopus citations

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial

Beer, T. M., Hotte, S. J., Saad, F., Alekseev, B., Matveev, V., Fléchon, A., Gravis, G., Joly, F., Chi, K. N., Malik, Z., Blumenstein, B., Stewart, P. S., Jacobs, C. A. & Fizazi, K., Nov 2017, In : The Lancet Oncology. 18, 11, p. 1532-1542 11 p.

Research output: Contribution to journalArticle

31 Scopus citations

Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo

Flamiatos, J. F., Beer, T. M., Graff, J. N., Eilers, K. M., Tian, W., Sekhon, H. S. & Garzotto, M., May 1 2017, In : BJU international. 119, 5, p. 709-716 8 p.

Research output: Contribution to journalArticle

13 Scopus citations

Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates

Bergstrom, C. P., Ruffell, B., Ho, C. M. T., Higano, C. S., Ellis, W. J., Garzotto, M., Beer, T. M. & Graff, J. N., Jan 2017, In : Anti-Cancer Drugs. 28, 1, p. 120-126 7 p.

Research output: Contribution to journalArticle

10 Scopus citations

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial

Alumkal, J. J., Chowdhury, S., Loriot, Y., Sternberg, C. N., de Bono, J. S., Tombal, B., Carles, J., Flaig, T. W., Dorff, T. B., Phung, D., Forer, D., Noonberg, S. B., Mansbach, H., Beer, T. M. & Higano, C. S., Oct 2017, In : Clinical Genitourinary Cancer. 15, 5, p. 610-617.e3

Research output: Contribution to journalArticle

7 Scopus citations

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

Beer, T. M., Armstrong, A. J., Rathkopf, D., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Evans, C. P., Kim, C. S., Kimura, G., Miller, K., Saad, F., Bjartell, A. S., Borre, M., Mulders, P., Tammela, T. L., Parli, T., Sari, S., van Os, S., Theeuwes, A. & 1 others, Tombal, B., Feb 1 2017, In : European Urology. 71, 2, p. 151-154 4 p.

Research output: Contribution to journalArticle

103 Scopus citations
17 Scopus citations

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: An in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

Devlin, N., Herdman, M., Pavesi, M., Phung, D., Naidoo, S., Beer, T. M., Tombal, B., Loriot, Y., Ivanescu, C., Parli, T., Balk, M. & Holmstrom, S., Jun 23 2017, In : Health and Quality of Life Outcomes. 15, 1, 130.

Research output: Contribution to journalArticle

8 Scopus citations

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer

Friedlander, T. W., Graff, J. N., Zejnullahu, K., Anantharaman, A., Zhang, L., Paz, R., Premasekharan, G., Russell, C., Huang, Y., Kim, W., Aggarwal, R. R., Lin, A. M., Fong, L., Alumkal, J. J., Beer, T. M., Sharifi, N., Alyamani, M., Dittamore, R., Small, E. J., Paris, P. L. & 1 others, Ryan, C. J., Dec 2017, In : Clinical Genitourinary Cancer. 15, 6, p. 733-741.e1

Research output: Contribution to journalArticle

8 Scopus citations

In reply

Beer, T. T. & Prasad, V., Nov 1 2017, In : JAMA oncology. 3, 11, p. 1588-1589 2 p.

Research output: Contribution to journalLetter

2 Scopus citations

Management of anticoagulation in patients with prostate cancer receiving enzalutamide

Shatzel, J. J., Daughety, M. M., Olson, S. R., Beer, T. T. & Deloughery, T., Nov 1 2017, In : Journal of Oncology Practice. 13, 11, p. 720-727 8 p.

Research output: Contribution to journalReview article

4 Scopus citations

Management of castration-resistant, taxane-resistant prostate cancer

Beer, T. T., Aug 15 2017, In : ONCOLOGY (United States). 31, 8, p. 1-5 5 p.

Research output: Contribution to journalArticle

Management of Castration-Resistant, Taxane-Resistant Prostate Cancer

Beer, T. M., Aug 15 2017, In : Oncology (Williston Park, N.Y.). 31, 8, p. 633-636 4 p.

Research output: Contribution to journalArticle

2 Scopus citations

Molecular testing in patients with castration-resistant prostate cancer and its impact on clinical decision making

Tao, D. L., Bailey, S., Beer, T. M., Foss, E., Beckett, B., Fung, A., Foster, B. R., Guimaraes, A., Cetnar, J. P., Graff, J. N., Eilers, K. M., Small, E. J., Corless, C. L., Thomas, G. V. & Alumkal, J. J., 2017, In : JCO Precision Oncology. 2017, 1, p. 1-11 11 p.

Research output: Contribution to journalArticle

5 Scopus citations

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

Armstrong, A. J., Halabi, S., Healy, P., Alumkal, J. J., Winters, C., Kephart, J., Bitting, R. L., Hobbs, C., Soleau, C. F., Beer, T. M., Slottke, R., Mundy, K., Yu, E. Y. & George, D. J., Aug 2017, In : European Journal of Cancer. 81, p. 228-236 9 p.

Research output: Contribution to journalArticle

32 Scopus citations

Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer

Kim, C. S., Choi, Y. D., Lee, S. E., Lee, H. M., Ueda, T., Yonese, J., Fukagai, T., Chiong, E., Lau, W., Abhyankar, S., Theeuwes, A., Tombal, B., Beer, T. M. & Kimura, G., Jul 1 2017, In : Medicine (United States). 96, 27, e7223.

Research output: Contribution to journalArticle

7 Scopus citations

Precision, complexity and stigma in advanced prostate cancer terminology: It is time to move away from 'castration-resistant' prostate cancer

ANZUP Consumer Advisory Panel, Aug 1 2017, In : Annals of Oncology. 28, 8, p. 1692-1694 3 p.

Research output: Contribution to journalEditorial

4 Scopus citations

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: Post hoc analysis of PREVAIL

Bryce, A. H., Alumkal, J. J., Armstrong, A., Higano, C. S., Iversen, P., Sternberg, C. N., Rathkopf, D., Loriot, Y., De Bono, J., Tombal, B., Abhyankar, S., Lin, P., Krivoshik, A., Phung, D. & Beer, T. M., Jun 1 2017, In : Prostate Cancer and Prostatic Diseases. 20, 2, p. 221-227 7 p.

Research output: Contribution to journalArticle

19 Scopus citations

Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer

Beer, T. T., Kwon, E. D., Drake, C. G., Fizazi, K., Logothetis, C., Gravis, G., Ganju, V., Polikoff, J., Saad, F., Humanski, P., Piulats, J. M., Mella, P. G., Ng, S. S., Jaeger, D., Parnis, F. X., Franke, F. A., Puente, J., Carvajal, R., Sengeløv, L., McHenry, M. B. & 3 others, Varma, A., Van Den Eertwegh, A. J. & Gerritsen, W., Jan 1 2017, In : Journal of Clinical Oncology. 35, 1, p. 40-47 8 p.

Research output: Contribution to journalArticle

220 Scopus citations